Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Suzhou
Clinical trial register · China

Clinical Trials in Suzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Soochow University115 Second Affiliated Hospital of Soochow University16 Capital Medical University9 Novartis Pharmaceuticals8 Takeda7
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Suzhou

424 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Chunshui He
Observational
600
Beijing, Xiamen, Hangzhou, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu
2027-01-01
Recruiting
Amgen
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Zhengzhou, Wuhan, Nanjing, Suzhou
2026-12-18
Recruiting
Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care
NCT07372027Hemodialysis Access, Arteriovenous Fistula, Arteriovenous Fistula Cannulation, Vascular Access
Suzhou Municipal Hospital of Anhui Province
Not applicable
100
Suzhou
2026-12-15
Recruiting
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Phase 1
20
Changsha, Suzhou
2026-10-31
Not yet open
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
NCT07902596Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Observational
2,000
Shijiazhuang, Lianyungang, Nanjing, Suzhou, Qingdao, Shanghai
2026-10-25
Recruiting
U69-CART-Cells For R/R T-ALL
NCT07350863Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University
Phase 1
12
Suzhou
2026-10-25
Not yet open
Triastek, lnc.
Phase 1
18
Suzhou
2026-10
Not yet open
The Fourth Affiliated Hospital of Soochow University
Not applicable
474
Suzhou, Shanghai
2026-09-30
Not yet open
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1
6
Suzhou
2026-09-28
Not yet open
yifang zhu
Phase 2/3
726
Suzhou
2026-09-20
Recruiting
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-17
Recruiting
UCB Biopharma SRL
Phase 3
100
Beijing, Chongqing, Nanchang, Suzhou
2026-09-16
Recruiting
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Recruiting
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
NCT07760454Relapsed/Refractory Multiple Myeloma
UCARsgen Biotech Limited
Phase 1/2
68
Suzhou, Shanghai
2026-09-03
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
15
Suzhou
2026-09-01
Not yet open
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
204
Guangzhou, Suzhou
2026-09
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
636
Bozhou, Hefei, Suzhou, Beijing, Fuzhou, Lanzhou, Qingyang, Dongguan
2026-08-21
Not yet open
The First Affiliated Hospital of Soochow University
Phase 2
39
Suzhou
2026-08-20
Recruiting
DEC003M in Prostate Cancer
NCT07657806Advanced Prostate Cancer
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Beijing, Suzhou, Chengdu, Hangzhou, Wenzhou, Chongqing
2026-08-19
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chaohu, Jinan, Linfen, Shanghai, Suzhou, Tianjin, Wenzhou
2026-08-14
Recruiting
Probiotics Improve Constipation
NCT07765004Constipation
Wecare Probiotics Co., Ltd.
Not applicable
76
Suzhou
2026-08-07
Recruiting
Beijing Tiantan Hospital
Observational
3,000
Beijing, Zhengzhou, Wuhan, Suzhou, Nanchang, Shanghai, Chengdu, Hangzhou
2026-08-03
Not yet open
Hangzhou PhecdaMed Co., Ltd.
Phase 3
300
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2026-08-03
Not yet open
Safety and Feasibility of FMT for Immune Recovery After HSCT
NCT07755319Humoral Immunodeficiency, Hematopoietic Stem Cell Transplantation
DrugFecal Microbiota Transplantation
The First Affiliated Hospital of Soochow University
Phase 1/2
86
Suzhou
2026-08-01
Not yet open
Cousin vs. Sibling Donors in Haplo-HSCT
NCT07662382Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor
The First Affiliated Hospital of Soochow University
Observational
1,000
Suzhou
2026-08-01
Not yet open
Children's Hospital of Soochow University
Not applicable
30
Suzhou
2026-08
Not yet open
A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients
NCT07762508Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)
DrugsAntithymocyte globulin·Busulfan·Ara-C·Cytarabine
The First Affiliated Hospital of Soochow University
Not applicable
42
Suzhou
2026-08
Not yet open
U96-CAR-T-Cells For R/R B-ALL
NCT07511426Relapsed or Refractory B Cell Leukemia and Lymphoma
The First Affiliated Hospital of Soochow University
Phase 1
30
Suzhou
2026-07-30
Recruiting
Adults With Constipation
NCT07529457Constipation
Wecare Probiotics Co., Ltd.
Not applicable
70
Suzhou
2026-07-24
Not yet open
The First Affiliated Hospital of Soochow University
Phase 2
96
Suzhou
2026-07-22
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
62
Suzhou
2026-07-15
Not yet open
Younger vs. Older Donors in Allo-HSCT: TTE
NCT07666568A Target Trial Emulation Study, Donor Age, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
The First Affiliated Hospital of Soochow University
Observational
5,000
Suzhou
2026-07-15
Recruiting
Angitia Biopharmaceuticals Guangzhou Limited
Phase 2
48
Beijing, Shenzhen, Changsha, Suzhou, Shanghai
2026-07-14
Recruiting
Polypills Approach for Multiple Cardiovascular Risk Factors
NCT07679828Hypertension, Dyslipidemia, Diabetes
China Medical University, China
Not applicable
8,252
Zhengzhou, Chifeng, Tongliao, Kunshan, Suzhou, Taizhou, Jinzhou, Panjin
2026-07-11
Recruiting
Huashan Hospital
Phase 2
90
Fuzhou, Guangzhou, Guiyang, Liupanshui, Zunyi, Suzhou, Ganzhou, Xining
2026-07-08
Recruiting
ShanShan Li
Observational
300
Shenzhen, Huai'an, Suzhou, Xuzhou, Dongying, Shanghai, Changzhou, Jiaozuo
2026-07-02
Not yet open
The First Affiliated Hospital of Soochow University
Phase 4
20
Suzhou
2026-07-01
Not yet open
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
NCT07667517Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
DrugFinerenone
First Affiliated Hospital of Zhejiang University
Phase 4
148
Chongqing, Fuzhou, Foshan, Guangzhou, Nantong, Suqian, Suzhou, Xi'an
2026-07-01
Recruiting
Climb Bio, Inc.
Phase 1/2
30
Mianyang, Baoji, Beijing, Bengbu, Changsha, Hefei, Nanchang, Suzhou
2026-06-30
Recruiting
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Not yet open
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
NCT07606937Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Early Phase 1
12
Beijing, Guangzhou, Suzhou, Shanghai, Chengdu, Tianjin
2026-06-12
Not yet open
Probiotics for Constipation Relief in Adults
NCT07507955Functional Constipation
Wecare Probiotics Co., Ltd.
Not applicable
105
Suzhou
2026-06-10
Recruiting
Probiotic Improve Constipation
NCT07462481Constipation
Wecare Probiotics Co., Ltd.
Not applicable
105
Suzhou
2026-06-10
Recruiting
Shanghai Zhongshan Hospital
Not applicable
420
Chongqing, Fuzhou, Xiamen, Wuhan, Nanjing, Suzhou, Shanghai, Luzhou
2026-06-10
Recruiting
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Phase 1/2
60
Suzhou
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Chengdu, Beijing, Jinan, Shanghai, Suzhou, Wuhan
2026-06-03
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
99
Suzhou
2026-06-02
Not yet open
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
NCT07635485Hypoplastic Acute Myeloid Leukemia, Secondary AML (Adult)
DrugsAzacitidine·Venetoclax
The First Affiliated Hospital of Soochow University
Not applicable
50
Suzhou
2026-06-01
Recruiting
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2026-06-01
Recruiting
CMV-CMI in csCMVi After HSCT
NCT07688759Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
The First Affiliated Hospital of Soochow University
Observational
40
Suzhou
2026-06-01
By invitation
Nanjing First Hospital, Nanjing Medical University
Not applicable
184
Nanjing, Suzhou
2026-06-01
Not yet open
The Hong Kong Polytechnic University
Not applicable
54
Kunshan, Suzhou, Suzhu
2026-06-01
Recruiting
Second Affiliated Hospital of Soochow University
Early Phase 1
30
Suzhou
2026-06-01
Recruiting
VA Consolidation in Intermediate-Risk AML
NCT07672262Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy
DrugVenetoclax and azacitidine
The First Affiliated Hospital of Soochow University
Phase 2
226
Suzhou
2026-06-01
Not yet open
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
NCT07575412Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
180
Suzhou
2026-06
Not yet open
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
NCT07562568Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell
The First Affiliated Hospital of Soochow University
Phase 2
160
Suzhou
2026-06
Recruiting
UCB Biopharma SRL
Phase 3
120
Beijing, Chengdu, Chongqing, Nanchang, Suzhou
2026-05-27
Active, closed
The First Affiliated Hospital of Soochow University
Early Phase 1
12
Suzhou
2026-05-20
Active, closed
First Hospital of China Medical University
Not applicable
6,800
Cangzhou, Suzhou, Panjin, Shenyang, Jinzhou, Tianjin
2026-05-14
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
VABu Conditioning in Elderly AML HSCT
NCT07583888Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University
Phase 2/3
20
Suzhou
2026-05-07
Recruiting
Novo Nordisk A/S
Phase 3
300
Beijing, Nanjing, Suzhou, Zhenjiang, Huzhou
2026-05-05
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
The First Affiliated Hospital of Soochow University
Observational
100
Suzhou
2026-05-01
Not yet open
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
NCT07609446Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma
DrugsPomalidomide·Prednisone
The First Affiliated Hospital of Soochow University
Observational
30
Suzhou
2026-05-01
Recruiting
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
NCT07463651Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance Therapy
DrugsGilteritinib·Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3
594
Suzhou, Shanghai
2026-05-01
Not yet open
The First Affiliated Hospital of Soochow University
Phase 2
52
Suzhou
2026-05-01
Recruiting
Sinomune Pharmaceutical Co., Ltd
Phase 1
48
Suzhou
2026-04-24
Recruiting
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
NCT07303777Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Atom Therapeutics Co., Ltd
Phase 2
200
Beijing, Dalian, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Suzhou
2026-04-23
Recruiting
Capital Medical University
Phase 3
348
Huaibei, Suzhou, Heyuan, Maoming, Qinhuangdao, Tangshan, Anyang, Hebi
2026-04-22
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
40
Zhengzhou, Suzhou, Xi’an, Hangzhou
2026-04-16
Recruiting
magAssist, Inc.
Not applicable
204
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an
2026-04-09
Recruiting
Effect of VR-MBCT in Chronic Nonspecific Low Back Pain
NCT07589790Chronic Non-specific Low Back Pain
The First Affiliated Hospital of Soochow University
Not applicable
214
Suzhou
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Baotou, Nanjing, Suzhou, Changchun
2026-04-01
Recruiting
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
NCT07500753Relapsed or Refractory Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
The First Affiliated Hospital of Soochow University
Not applicable
30
Suzhou
2026-04-01
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
24
Suzhou
2026-03-30
Recruiting
Zhangjiagang First People's Hospital
Phase 4
520
Suzhou
2026-03-29
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 1
3
Suzhou
2026-03-27
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
124
Suzhou
2026-03-24
Recruiting
BeOne Medicines
Phase 1
98
Beijing, Chongqing, Fuzhou, Shijiazhuang, Changsha, Suzhou, Shenyang, Shanghai
2026-03-19
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
15
Beijing, Suzhou, Jinan, Tianjin, Hangzhou
2026-03-17
Recruiting
BY002 IIT Study in R/R Acute Leukemia
NCT07270770Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia
DrugBY002
The First Affiliated Hospital of Soochow University
Phase 1
18
Suzhou
2026-03-15
Recruiting
Romiplostim for Oral TPO-RA Resistant ITP
NCT07612319Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
DrugRomiplostim
The First Affiliated Hospital of Soochow University
Not applicable
60
Suzhou
2026-03-15
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Active, closed
Mass Balance Study of [14C] D-2570
NCT07411742Mass Balance Study
InventisBio Co., Ltd
Phase 1
8
Suzhou
2026-03-10
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
Gelaspan vs Crystalloid Therapy in Sepsis
NCT07172451Sepsis, Intra-Abdominal Infections
Shanghai Zhongshan Hospital
Phase 4
318
Guangzhou, Nanjing, Suzhou, Xuzhou, Shanghai, Chengdu, Tianjing, Hangzhou
2026-02-13
Recruiting
Eli Lilly and Company
Phase 2
450
Changsha, Chengdu, Hangzhou, Suzhou, Tianjin, Wuhu, Xi'an, Zhumadian
2026-02-10
Recruiting
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
NCT07425782Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk
The First Affiliated Hospital of Soochow University
Phase 2
216
Suzhou
2026-02-01
Not yet open
Zeng Changhao
Not applicable
474
Suzhou, Zhenzhou
2026-02
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
66
Suzhou
2026-01-31
Not yet open
China National Biotec Group Company Limited
Observational
600
Suzhou, Handan, Yancheng, Hanzhong, Yuncheng, Mianyang
2026-01-30
Recruiting
Shanghai Mental Health Center
Observational
121
Suzhou, Xuzhou, Shanghai, Hangzhou, Ningbo
2026-01-24
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2026-01-15
Recruiting
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Zhengzhou, Suzhou, Changchun, Dalian, Xi'an
2026-01-15
Not yet open
Osteoporotic Vertebral Compression Fracture Cohort Study
NCT07321795OVCF Database, Cohort Study
Wangjing Hospital, China Academy of Chinese Medical Sciences
Observational
200
Hunan, Suzhou, Weihai, Beijing
2026-01-10
Recruiting
Gan & Lee Pharmaceuticals.
Phase 1
138
Suzhou
2026-01-09
Active, closed
The First Affiliated Hospital of Soochow University
Phase 2
25
Suzhou
2026-01-01
Active, closed
Efficacy of Vitamin D in Post-Stroke Cognitive Impairment
NCT07767214Post-Stroke Cognitive Impairment (PSCI)
Suzhou Municipal Hospital of Anhui Province
Not applicable
300
Suzhou
2026-01-01
Recruiting
Bin Gu
Phase 2
25
Suzhou
2026-01-01
Active, closed
The Children's Hospital of Zhejiang University School of Medicine
Observational
300
Hefei, Suzhou, Kunming, Hangzhou, Wenling
2026-01-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
35
Suzhou
2026-01-01
Recruiting
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01-01
Recruiting
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01
Not yet open
Second Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2025-12-27
Active, closed
Capital Medical University
Not applicable
208
Fuyang, Suzhou, Beijing, Zhoukou, Shihezi
2025-12-18
Recruiting
Capital Medical University
Phase 3
1,192
Anqing, Bozhou, Fuyang, Ma’anshan, Suzhou, Wuhu, Beijing, Fuzhou
2025-12-18
Not yet open
Zhao Jun
Observational
200
Suzhou
2025-12-17
Recruiting
Lei Yunshang Group
Phase 1
120
Suzhou
2025-12-15
Not yet open
Second Affiliated Hospital of Soochow University
Phase 3
312
Suzhou
2025-12-15
Recruiting
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
15
Suzhou
2025-12-12
Recruiting
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
Danyang Huichuang Medical Equipment Co., Ltd.
Phase 3
320
Beijing, Shijiazhuang, Baotou, Suzhou, Xi'an, Shanghai, Taiyuan, Tianjin
2025-12-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
64
Suzhou
2025-12-08
Active, closed
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
NCT07284927Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
DrugLV009
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1
10
Suzhou
2025-12-03
Recruiting
Sanofi
Phase 2
37
Beijing, Shanghai, Shenzhen, Suzhou
2025-12-02
Recruiting
Second Affiliated Hospital of Soochow University
Phase 2
127
Suzhou
2025-12-01
Recruiting
PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
NCT07267234Solid Cancer, Lymphopenia, Radiotherapy, Immune Checkpoint Inhibitor
Second Affiliated Hospital of Soochow University
Phase 2
65
Suzhou
2025-12-01
Not yet open
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
29
Suzhou
2025-11-30
Recruiting
Shanghai RAAS Blood Products Co., Ltd.
Phase 2
24
Changsha, Hefei, Jinan, Nanning, Suzhou, Taiyuan, Tangshan, Tianjin
2025-11-26
Recruiting
IVIEW Therapeutics Inc.
Phase 1/2
6
Suzhou
2025-11-19
Recruiting
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
NCT07805967Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Second Affiliated Hospital of Soochow University
Observational
500
Changshu, Huai'an, Kunshan, Nanjing, Nantong, Suqian, Suzhou, Xuzhou
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Recruiting
Ascentage Pharma Group Inc.
Phase 1
48
Suzhou
2025-11-11
Recruiting
A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT
NCT07559695Menin Inhibitors, Acute Leukemia, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy
The First Affiliated Hospital of Soochow University
Observational
20
Suzhou
2025-11-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 4
40
Suzhou
2025-11-01
Recruiting
Hao Yonggang
Not applicable
910
Suzhou
2025-11-01
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
12
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Active, closed
A Phase Ⅰ b Clinical Study of ART101 Injection
NCT07614308Hypertension (HTN)
Arnatar Therapeutics, Inc.
Phase 1
16
Suzhou
2025-10-27
Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
NCT07208097Intracerebral Haemorrhage, Minimally Invasive Treatment
Tongji Hospital
Not applicable
768
Anqing, Hefei, Suzhou, Guangzhou, Nanning, Bijie, Guiyang, Kaili
2025-10-25
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
23
Suzhou
2025-10-24
Recruiting
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.
Early Phase 1
36
Bengbu, Hefei, Nanjing, Suzhou, Wenzhou
2025-10-14
Recruiting
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Children's Hospital of Soochow University
Observational
150
Suzhou
2025-10-13
Recruiting
Celgene
Phase 1/2
62
Suzhou, Shanghai
2025-10-07
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
224
Suzhou, Xuzhou, Hangzhou
2025-10-01
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Recruiting
Children's Hospital of Soochow University
Not applicable
1,380
Suzhou
2025-09-26
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
NCT07451912Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
DrugVenetoclax
The First Affiliated Hospital of Soochow University
Phase 1/2
29
Suzhou
2025-09-15
Recruiting
The University of Hong Kong
Not applicable
232
Suzhou
2025-09-08
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
27
Suzhou
2025-09-01
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
30
Suzhou
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
Second Affiliated Hospital of Soochow University
Phase 4
580
Suzhou, Shijiazhuang, Zhoukou, Bayan Nur, Huai'an, Suqian, Taizhou, Xi'an
2025-08-30
Recruiting
Sanofi
Phase 3
90
Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan
2025-08-18
Recruiting
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
Probiotics and Non-Organic Gastrointestinal Improvement
NCT07081100Gastrointestinal Function
Wecare Probiotics Co., Ltd.
Not applicable
50
Suzhou
2025-08-05
Recruiting
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
NCT07101497Menin Inhibitors, Post Hematopoietic Stem Cell Transplantation, Maintenance Therapy, Acute Leukemia
DrugBN104
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2025-08-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
18
Suzhou
2025-07-30
Recruiting
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Recruiting
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
NCT06730256Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University
Early Phase 1
24
Suzhou
2025-07-23
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
9
Suzhou
2025-07-14
Active, closed
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2025-07-10
Not yet open
Prince of Songkla University
Not applicable
90
Suzhou
2025-07-09
Active, closed
Sanofi
Phase 2
105
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Recruiting
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
NCT07072247Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University
Phase 1
9
Suzhou
2025-07-07
By invitation
The First Affiliated Hospital of Soochow University
Not applicable
10
Suzhou
2025-07-03
Recruiting
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
20
Suzhou
2025-07-03
By invitation
Junbo Ge
Not applicable
40
Hefei, Suzhou, Shanghai
2025-07-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
12
Suzhou
2025-06-20
Active, closed
Duke Kunshan University
Not applicable
600
Suzhou
2025-06-20
Recruiting
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Not yet open
The First Affiliated Hospital of Soochow University
Phase 2/3
30
Suzhou
2025-06-01
Recruiting
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
NCT07007949Acute Myeloid Leukemia, IDH1 Gene Mutation, Ivosidenib
DrugsVenetoclax and azacitidine·Ivosidenib
The First Affiliated Hospital of Soochow University
Phase 2
42
Suzhou
2025-06-01
Recruiting
Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules
NCT07047573Lung Cancer (Diagnosis), Pulmonary Nodule Persistent
Zhao Jun
Observational
150
Suzhou
2025-06-01
Recruiting
Anhui Provincial Hospital
Observational
600
Hefei, Suzhou, Ningbo
2025-06-01
Recruiting
Second Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2025-06-01
Not yet open
Starna Therapeutics
Early Phase 1
30
Suzhou
2025-06
Recruiting
GeneCradle Inc
Phase 3
50
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
2025-05-27
Recruiting
Peripheral Blood KIT-D816V Mutation in Adult Systemic Mastocytosis
NCT07562542Systemic Mastocytosis, KIT-D816V Mutation
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2025-05-19
Not yet open
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
DrugUTAA91
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1
15
Suzhou
2025-05-18
Recruiting
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
NCT06985485Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
The First Affiliated Hospital of Soochow University
Phase 2
26
Suzhou
2025-05-17
Recruiting
A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
NCT07028073Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation, Avapritinib
The First Affiliated Hospital of Soochow University
Phase 1/2
78
Suzhou
2025-05-15
Active, closed
Wellizen Australia
Phase 2
16
Suzhou
2025-05-09
Recruiting
The First Affiliated Hospital of Soochow University
Observational
300
Suzhou
2025-05-01
Recruiting
Shanghai East Hospital
Phase 3
2,423
Suzhou, Shanghai
2025-04-30
Recruiting
Dapagliflozin in Allo-HCT for aGVHD
NCT06626737Graft-versus-host Disease (GVHD)
DrugDapagliflozin
The First Affiliated Hospital of Soochow University
Phase 2
72
Suzhou
2025-04-26
Recruiting
Wecare Probiotics Co., Ltd.
Not applicable
80
Suzhou
2025-04-10
Not yet open
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
NCT06838520Prostate Cancer (Adenocarcinoma)
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Changzhou, Nanjing, Suzhou, Yangzhou
2025-04-01
Recruiting
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
NCT07012447Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, Nos
DrugsAra-C·Venclexta·Cytarabine·Azacitidine
yuejun Liu
Phase 2
32
Suzhou
2025-04-01
Recruiting
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
NCT07564453B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
DrugBlinatumomab
The First Affiliated Hospital of Soochow University
Phase 2
101
Suzhou
2025-04-01
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
Soochow University
Observational
400
Suzhou
2025-03-31
Active, closed
Soochow University
Not applicable
1,486
Suzhou
2025-03-24
Recruiting
Zhangjiagang First People's Hospital
Not applicable
552
Suzhou
2025-03-24
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
40
Suzhou
2025-03-18
Active, closed
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
Pfizer
Phase 3
723
Beijing, Chongqing, Shijiazhuang, Nanjing, Suzhou, Xi'an, Xianyang, Shanghai
2025-03-11
Not yet open
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation
The First Affiliated Hospital of Dalian Medical University
Not applicable
1,334
Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai
2025-03-03
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xi’an
2025-03-01
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Recruiting
Investigation of Tetralogy of Fallot in Neonates
NCT06822400Tetralogy of Fallot (TOF), Pulmonary Stenosis, Ventricular Septal Defects (VSD), Double Outlet Right Ventricle
Beijing Anzhen Hospital
Not applicable
160
Beijing, Chengdu, Shanghai, Shenzhen, Suzhou
2025-03-01
Not yet open
Nanjing Broad Biopharmaceutical Ltd.
Observational
300
Huaian, Suzhou, Xuzhou, Yangzhou
2025-03-01
Recruiting
Children's Hospital of Soochow University
Not applicable
90
Wuhan, Suzhou, Changchun
2025-03
Recruiting
Shanghai Kechow Pharma, Inc.
Phase 1
52
Suzhou
2025-02-28
Recruiting
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
By invitation
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 1
78
Suzhou
2025-02-26
Recruiting
Wecare Probiotics Co., Ltd.
Not applicable
84
Suzhou
2025-02-25
Not yet open
The First Affiliated Hospital of Soochow University
Not applicable
158
Suzhou
2025-02-15
Active, closed
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Chifeng, Suzhou, Beijing, Chengdu, Fujian
2025-02-10
Recruiting
The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders
NCT06797284Insomnia Chronic, Narcolepsy, REM Sleep Behavior Disorder
Second Affiliated Hospital of Soochow University
Not applicable
20
Suzhou
2025-02-01
Recruiting
Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
NCT06816134Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Transplantation, Stem Cell, Conditioning Therapy
The First Affiliated Hospital of Soochow University
Phase 2
48
Suzhou
2025-01-30
Recruiting
BeOne Medicines
Phase 1/2
258
Beijing, Guangzhou, Suzhou
2025-01-23
Not yet open
Second Affiliated Hospital of Soochow University
Not applicable
200
Suzhou
2025-01-18
Recruiting
First Affiliated Hospital of Guangxi Medical University
Observational
500
Nanning, Qinzhou, Wuzhou, Yulin, Suzhou
2025-01-06
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2025-01-02
Recruiting
A Technique Improves Urinary Continence in Patients Undergoing Laparoscopic Radical Prostatectomy
NCT06754488Posterior Bladder Wall Reconstruction, Anterior Bladder Wall Reconstruction, Anterior Bladder Wall Suspension
Suzhou Municipal Hospital
Not applicable
120
Suzhou
2025-01-01
By invitation
Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease
NCT07176091Parkinsonism, Transcranial Magnetic Stimilation, Intermittent Theta Burst Stimulation, Primary Motor Cortex
Second Affiliated Hospital of Soochow University
Not applicable
90
Suzhou
2025-01-01
Recruiting
Chen Suning
Phase 1/2
135
Suzhou
2024-12-25
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
330
Suzhou
2024-12-16
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
20
Suzhou
2024-12-10
Not yet open
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
NCT06673459T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
The First Affiliated Hospital of Soochow University
Phase 3
430
Suzhou
2024-12-01
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2024-12-01
Recruiting
The First Affiliated Hospital of Soochow University
Early Phase 1
18
Suzhou
2024-12-01
Recruiting
Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial
NCT07581756Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Chronic Diarrhea
The First Affiliated Hospital of Soochow University
Not applicable
46
Suzhou
2024-12-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
400
Suzhou
2024-12-01
Not yet open
Geneplus-Beijing Co. Ltd.
Observational
80
Suzhou
2024-12-01
Not yet open
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
10
Suzhou
2024-12
Recruiting
The Impact of Local Anesthetic Solution Temperature on Epidural-related Maternal Fever
NCT06682416Epidural Related Maternal Fever, Analgesia, Epidural, Fever, Intrapartum Fever
The First Affiliated Hospital of Soochow University
Not applicable
424
Suzhou
2024-11-30
Recruiting
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
NCT06682130Diffuse Large B-cell Lymphoma(DLBCL)
The First Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2024-11-10
Recruiting
Capital Medical University
Phase 3
1,184
Bengbu, Bozhou, Huaibei, Suzhou, Beijing, Haidian, Pinggu, Tongzhou
2024-11-07
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2024-11-01
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2024-11-01
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
47
Suzhou
2024-11-01
Active, closed
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Xiaoyan Shi
Not applicable
128
Suzhou
2024-09-28
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Recruiting
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
33
Beijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
2024-09-19
Recruiting
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2024-09-10
Recruiting
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1
10
Suzhou
2024-09-04
Not yet open
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
NCT06559644Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Early Phase 1
20
Suzhou
2024-09-01
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, Ürümqi, Wuhan
2024-08-26
Active, closed
Oneness Biotech Co., Ltd.
Phase 2/3
120
Jiangmen, Luoyang, Suzhou, Zhenjiang, Shenyang, Xi'an, Hangzhou, Guangzhou
2024-08-16
Recruiting
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
80
Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu
2024-08-16
Recruiting
A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects
NCT06599528Assisted Reproductive Technology, Female Infertility
Suzhou Centergene Pharmaceuticals Co.,Ltd.
Phase 1
48
Suzhou
2024-08-12
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
SciClone Pharmaceuticals
Observational
450
Suzhou
2024-08-08
Active, closed
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
DrugUstekinumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea
NCT06757491Repetitive Transcranial Magnetic Stimulation, Chronic Visceral Pain, Functional Magnetic Resonance Imaging, IBS (Irritable Bowel Syndrome)
The First Affiliated Hospital of Soochow University
Not applicable
42
Suzhou
2024-08-01
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
172
Suzhou
2024-07-29
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2024-07-10
Active, closed
Tianjin Medical University General Hospital
Phase 2/3
102
Hefei, Lanzhou, Shijiazhuang, Harbin, Zhenzhou, Ordos, Changzhou, Suzhou
2024-07-09
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
197
Suzhou
2024-07-08
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an
2024-06-14
Recruiting
The First Affiliated Hospital of Soochow University
Phase 4
59
Suzhou
2024-06-12
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Active, closed
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Not yet open
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Active, closed
The First Affiliated Hospital of Soochow University
Phase 2/3
44
Suzhou
2024-05-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
30
Suzhou
2024-04-25
Active, closed
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4
100
Beijing, Suzhou, Jinan, Jining, Taiyuan
2024-04-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou
2024-04-03
Recruiting
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06279026Relapsed/Refractory Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Not applicable
15
Suzhou
2024-04-01
Recruiting
VA vs DA for Newly Diagnosed Hig-risk AML
NCT05939180Acute Myeloid Leukemia
DrugsDaunorubicin·Venetoclax
The First Affiliated Hospital of Soochow University
Phase 2/3
116
Suzhou
2024-04-01
Recruiting
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
NCT06381817Acute T Cell Lymphoblastic Leukemia, Haploidentical Hematopoietic Stem Cell Transplantation, Cord Blood
The First Affiliated Hospital of Soochow University
Phase 3
146
Suzhou
2024-04-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1
4
Suzhou
2024-04-01
Recruiting
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
18
Suzhou
2024-03-26
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Active, closed
Nanjing Medical University
Not applicable
934
Suzhou
2024-03-08
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Recruiting
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
DrugsIdarubicin Hydrochloride·Granulocyte Colony-Stimulating Factor·Avapritinib·Decitabine
Children's Hospital of Soochow University
Phase 2
50
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-03-01
Recruiting
Suzhou Municipal Hospital
Not applicable
30
Nanjing, Nantong, Suzhou
2024-03-01
Recruiting
Suzhou Municipal Hospital
Not applicable
300
Suzhou
2024-02-26
Not yet open
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
NCT06289959Lymphoma, Large B-Cell, Diffuse
Second Affiliated Hospital of Soochow University
Not applicable
30
Suzhou
2024-02-25
Recruiting
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
NCT06394011Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2024-02-15
Recruiting
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
NCT06250959ALL, Adult, Philadelphia-Negative ALL
DrugsBlinatumomab·Doxorubicin
Chen Suning
Phase 2
124
Suzhou
2024-02-05
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
32
Suzhou
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
Second Affiliated Hospital of Soochow University
Not applicable
34
Suzhou
2024-02-01
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Recruiting
Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion
NCT06155032Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
First Affiliated Hospital of Wannan Medical College
Not applicable
272
Fuyang, Hefei, Huainan, Huangshan City, Suzhou, Wuhu, Xiangyang
2024-01-04
Recruiting
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
55
Beijing, Guangzhou, Guiyang, Wuhan, Changsha, Suzhou, Xi’an, Chengde
2024-01-03
Active, closed
The First Affiliated Hospital of Soochow University
Phase 2
40
Suzhou
2024-01-01
Recruiting
Children's Hospital of Soochow University
Phase 2
500
Hefei, Guangzhou, Nanning, Kaifeng, Zhengzhou, Changsha, Suzhou, Xuzhou
2024-01-01
Recruiting
The First Affiliated Hospital of Soochow University
Early Phase 1
20
Suzhou
2024-01-01
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Qingdao, Shanghai
2023-12-29
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Recruiting
Southeast University, China
Not applicable
404
Hefei, Jinjiang, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Taizhou
2023-11-27
Recruiting
Second Affiliated Hospital of Soochow University
Observational
300
Suzhou
2023-11-17
Recruiting
Second Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2023-11-07
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Relma-cel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Active, closed
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
13
Suzhou
2023-10-29
Active, closed
A Study of BN104 in the Treatment of Acute Leukemia
NCT06052813ALL, Adult, AML, Adult, Acute Leukaemia, KMT2A Rearrangement
DrugBN104
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1/2
66
Suzhou
2023-10-19
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Recruiting
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
408
Beijing, Lanzhou, Shijiazhuang, Luoyang, Wuhan, Suzhou, Nanchong, Tianjin
2023-09-11
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
By invitation
The First Affiliated Hospital of Soochow University
Phase 2/3
98
Suzhou
2023-08-01
Recruiting
Venetoclax Combined With Azactidine in the Treatment of ALAL
NCT05901974Acute Leukemia of Ambiguous Lineage
DrugVenetoclax
Sheng-Li Xue, MD
Phase 2
23
Suzhou
2023-07-01
Not yet open
The First Affiliated Hospital of Soochow University
Phase 2
22
Suzhou
2023-07-01
By invitation
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2023-07-01
Recruiting
GlaxoSmithKline
Phase 1/2
123
Suzhou
2023-06-14
Recruiting
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
25
Suzhou
2023-06-01
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
Statins for Treatment of Primary Intracerebral Hemorrhage
NCT07088250Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage, Intracerebral Haemorrhage
The Second Hospital of Anhui Medical University
Not applicable
264
Anqing, Fuyang, Hefei, Huainan, Lu'an, Suzhou, Harbin, Kaifeng
2023-05-06
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
DrugsPanitumumab·Folfox·Cetuximab·Nab-paclitaxel
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Recruiting
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05768529Relapsed or Refractory Non-Hodgkin's Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2
100
Changsha, Suzhou, Shanghai
2023-03-28
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
43
Suzhou
2023-03-15
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
By invitation
FMT in Transplant-related Gastrointestinal Mucositis
NCT07622849Transplant-related Gastrointestinal Mucositis
DrugFecal microbiota
The First Affiliated Hospital of Soochow University
Observational
20
Suzhou
2023-03-01
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2/3
60
Suzhou
2023-03-01
Recruiting
GeneCradle Inc
Phase 1/2
18
Beijing, Shenyang, Suzhou
2023-02-25
Recruiting
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
DrugAzacitidine
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
198
Nanchang, Suzhou, Zhengzhou
2023-02-14
Recruiting
Zhao Jun
Observational
50
Suzhou
2023-02-12
Active, closed
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Suzhou Municipal Hospital
Phase 2
32
Suzhou
2023-01-16
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
Xuanwu Hospital, Beijing
Observational
16,000
Beijing, Changchun, Chengdu, Suzhou
2022-12-01
Recruiting
Huashan Hospital
Observational
1,255
Lanzhou, Harbin, Hohhot, Suzhou, Xuzhou, Shenyang, Jinan, Jining
2022-12-01
Recruiting
Construction of a Database for TMA
NCT05634928Thrombotic Microangiopathies
The First Affiliated Hospital of Soochow University
Observational
500
Suzhou
2022-12-01
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
4,500
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2022-12
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
120
Suzhou
2022-11-24
Recruiting
Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
NCT05349955Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease
Shanghai Zhongshan Hospital
Not applicable
5,600
Suzhou
2022-11-21
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Recruiting
Construction of a Database for TTP
NCT05571774TTP - Thrombotic Thrombocytopenic Purpura
The First Affiliated Hospital of Soochow University
Observational
500
Suzhou
2022-10-20
Active, closed
Healthguard Biomed
Not applicable
207
Suzhou
2022-10-19
Recruiting
CAV Regimen for R/R Ph- B-ALL
NCT05657652Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Not applicable
36
Suzhou
2022-10-01
Recruiting
CAV Regimen for R/R AML
NCT05657639Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University
Phase 2
68
Suzhou
2022-10-01
Active, closed
GlaxoSmithKline
Phase 3
110
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Suzhou, Wuhan
2022-09-06
Recruiting
Olverembatinib for FGFR1-rearranged Neoplasms
NCT05521204Myeloproliferative Neoplasm, Acute Leukemia
DrugOlverembatinib
The First Affiliated Hospital of Soochow University
Phase 2
20
Suzhou
2022-09-01
Recruiting
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961ALL, MRD-positive, Hematopoietic Stem Cell Transplantation
DrugInotuzumab Ozogamicin
Sheng-Li Xue, MD
Phase 2
42
Suzhou
2022-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
110
Suzhou
2022-07-06
Active, closed
Observational Study in Multiple System Atrophy
NCT05453058Multiple System Atrophy
H. Lundbeck A/S
Observational
90
Beijing, Changsha, Chengdu, Shanghai, Suzhou
2022-06-25
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2/3
124
Suzhou
2022-06-25
Active, closed
Intracranial Arterial Stenosis in Young Patients
NCT05844176Intracranial Arterial Stenosis
Capital Medical University
Observational
500
Suzhou, Shijiazhuang, Beijing, Zhengzhou
2022-06-01
Active, closed
The First Affiliated Hospital of Soochow University
Observational
1,000
Suzhou
2022-05-03
Recruiting
Urine and Ultrasound Screening for Kidney Disease in Children
NCT06018831Kidney Diseases, Diagnostic Techniques, Ultrasound, Urinalysis
Children's Hospital of Fudan University
Not applicable
13,000
Nantong, Suzhou
2022-04-12
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
28
Suzhou
2022-04-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou
2022-03-24
Active, closed
Genmab
Phase 1/2
49
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou
2022-03-10
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
92
Suzhou
2022-03-01
Recruiting
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Recruiting
Hrain Biotechnology Co., Ltd.
Early Phase 1
7
Suzhou
2022-01-26
Active, closed
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Active, closed
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
Takeda
Observational
72
Hefei, Beijing, Zhengzhou, Hohhot, Suzhou, Nanchang, Shenyang, Qingdao
2021-10-29
Active, closed
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
Light Therapy in Parkinson's Disease
NCT06129942Parkinson Disease, Sleep Disorder, Circadian Rhythm Disorders
Second Affiliated Hospital of Soochow University
Not applicable
50
Suzhou
2021-09-01
Active, closed
New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT05029141Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML
The First Affiliated Hospital of Soochow University
Phase 2
21
Suzhou
2021-09-01
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
DrugsCarboplatin/Paclitaxel·Anlotinib
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
By invitation
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
By invitation
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Shantou, Suzhou, Tianjin
2021-07-27
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Active, closed
Akeso
Phase 1/2
136
Suzhou
2021-06-18
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
318
Suzhou
2021-06-07
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Recruiting
Shanghai Juncell Therapeutics
Early Phase 1
50
Suzhou
2021-05-06
Active, closed
Takeda
Phase 3
77
Beijing, Wuhan, Suzhou, Tianjin
2021-04-14
Active, closed
Karyopharm Therapeutics Inc
Phase 2
112
Beijing, Wuhan, Nantong, Suzhou, Changchun, Hangzhou
2021-03-17
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Active, closed
A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
2,000
Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou
2021-02-01
Recruiting
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Active, closed
Amgen
Phase 1/2
181
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an
2021-01-04
Recruiting
Relationship Between "FODMAPs" and "GVHD"
NCT04660487Graft Versus Host Disease
The First Affiliated Hospital of Soochow University
Observational
100
Suzhou
2020-12-01
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou
2020-12-01
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan
2020-11-03
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
682
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2020-09-28
Active, closed
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
DrugTRS005
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Active, closed
Karyopharm Therapeutics Inc
Phase 2/3
501
Nanjing, Suzhou, Huangpu, Xuhui, Chengdu, Hangzhou
2020-09-03
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 3
232
Changsha, Chongqing, Hangzhou, Nanjing, Ningbo, Suzhou
2020-09-01
Recruiting
The Risk Factors of Cardiovascular Disease in Elderly Diabetic Patients: A Prospective Cohort Study
NCT04544527Diabetes Mellitus, Cardiovascular Diseases, Complication Diabetic
Shanghai Zhongshan Hospital
Observational
10,000
Suzhou
2020-09-01
Active, closed
PharmaEssentia
Phase 3
174
Beijing, Chongqing, Guangzhou, Wuhan, Suzhou, Shenyang, Xi'an, Jinan
2020-08-25
Active, closed
The First Affiliated Hospital of Soochow University
Phase 2
37
Suzhou
2020-01-19
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
31
Suzhou
2020-01-01
Active, closed
Pfizer
Phase 3
1,068
Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou
2019-12-30
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Active, closed
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1/2
50
Suzhou
2019-07-15
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
The First Affiliated Hospital of Soochow University
Phase 2
60
Suzhou
2019-07-01
Active, closed
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Recruiting
Eli Lilly and Company
Phase 3
190
Beijing, Chongqing, Nanjing, Suzhou
2019-04-05
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Zhengzhou, Suzhou, Changchun, Hangzhou, Tianjin
2018-10-04
Recruiting
Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation
NCT04146870Nutrition, Hematopoietic Stem Cell Transplantation
The First Affiliated Hospital of Soochow University
Observational
200
Suzhou
2018-10-01
Recruiting
Fudan University
Not applicable
4,052
Guiyang, Suzhou, Dalian, Shanghai
2018-07-01
Active, closed
The First Affiliated Hospital of Soochow University
Phase 1/2
43
Suzhou
2018-02-20
Active, closed
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
NCT03984968Acute Lymphoblastic Leukemia, Adult B-Cell
DrugCD19
The First Affiliated Hospital of Soochow University
Phase 1/2
40
Suzhou
2017-07-10
Recruiting
FMT in Gut aGVHD Treated
NCT03148743Acute-graft-versus-host Disease
DrugFecal microbiota
The First Affiliated Hospital of Soochow University
Observational
50
Suzhou
2017-05-16
Recruiting
The First Affiliated Hospital of Soochow University
Phase 1/2
10
Suzhou
2016-09
Active, closed
Shanghai Jiao Tong University School of Medicine
Phase 3
786
Fuding, Fuzhou, Quanzhou, Foshan, Guangzhou, Harbin, Jiangyin, Suzhou
2016-03
Active, closed
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
NCT03919240Acute Lymphoblastic Leukemia With Failed Remission
The First Affiliated Hospital of Soochow University
Phase 1/2
196
Suzhou
2015-12-01
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shanxi, Suzhou
2013-09-09
By invitation
Follow-up Study of ICUS and CCUS Patients
NCT04428489Myelodysplastic Syndromes
The First Affiliated Hospital of Soochow University
Observational
300
Suzhou
2011-01-01
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
20,000
Changzhou, Huai'an, Nanjing, Suqian, Suzhou
2008-01
Rows per page Showing 1–424 of 424
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/suzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 424 of those studies with a site in Suzhou.

How many clinical trials are recruiting in Suzhou?

272 of the 424 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 53 have not yet opened recruitment, 87 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Suzhou), 424 studies
PhaseStudiesRecruitingShare
Not applicable855820%
Phase 2835519.6%
Phase 3754017.7%
Observational593313.9%
Phase 1463810.8%
Phase 1/238279%
Early Phase 11393.1%
Phase 2/31353.1%
Phase 41272.8%

Most active sponsors

Lead sponsors with the most studies (Suzhou)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Soochow University11580
Second Affiliated Hospital of Soochow University1611
Capital Medical University95
Novartis Pharmaceuticals83
Takeda74
Wecare Probiotics Co., Ltd.76
AbbVie61
Amgen61
Children's Hospital of Soochow University65
BeOne Medicines55
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.